You are here:Home-Research Areas-Endocrine Disorders -Hyperparathyroidism

Request The Product List ofHyperparathyroidism Hyperparathyroidism

Cat. No. Product Name CAS No. Information
PC-63560

Velcalcetide

1262780-97-1

Velcalcetide (AMG-416, Velcalcetide, Etelcalcetide, KAI-4169) is a potent, peptide agonist of CaSR, dose-dependenty increases IP1 accumulation with EC50 of 25 uM in cell based assays; reduces parathyroid hormone (PTH) levels and corresponding decreases serum calcium, regardless of the baseline level of PTH in vivo.

Hyperparathyroidism

Approved

PC-35256

PCO371

1613373-33-3 PCO371 is a potent, selective, orally active, full agonist of the PTH type 1 receptor (PTHR1) with EC50 of 2.4 uM in cell-based assays, does not affect PTHR2; exhibits PTH-like biological activity in osteopenic ovariectomized (OVX) rats and in hypocalcemic thyroparathyroidectomized (TPTX) rats after oral administration; increases bone mineral density (BMD) and bone strength as effectively as PTH by intravenous administration in vivo.

Hyperparathyroidism

Phase 1 Clinical

PC-62909

Tecalcet

148717-54-8 Tecalcet (R-568;NPS R-568;KRN-568;NPS-568) is a calcimimetic acting agent and potent, selective positive allosteric modulator (agonist) of CaSR; potentiates the effects of extracellular Ca2+ on [Ca2+]i and PTH secretion (IC50=27 nM in bovine parathyroid cells) without effect in the absence of extracellular Ca2+, does not affect responses elicited by the homologous mGluRs.

Hyperparathyroidism

Phase 2 Discontinued

PC-62908

Tecalcet hydrochloride

177172-49-5 Tecalcet (R-568;NPS R-568;KRN-568;NPS-568) is a calcimimetic acting agent and potent, selective positive allosteric modulator (agonist) of CaSR; potentiates the effects of extracellular Ca2+ on [Ca2+]i and PTH secretion without effect in the absence of extracellular Ca2+, does not affect responses elicited by the homologous mGluRs; prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.

Hyperparathyroidism

Phase 2 Discontinued

PC-45906

Paricalcitol

131918-61-1 An analog of 1,25-dihydroxyergocalciferol that acts as a selective vitamin D receptor (VDR) activator; significantly decreases parathyroid hormone levels with no changes in calcium and phosphorous, also reduces serum concentrations of IL-6 and TNF-α compared to baseline; orally active.

Hyperparathyroidism

Approved

PC-45806

Doxercalciferol

54573-75-0 A synthetic analog of vitamin D with potential antineoplastic activity; has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells.

Hyperparathyroidism

Approved

PC-45804

Falecalcitriol

83805-11-2 A hexafluorinated analogue of 1,25(OH)2 vitamin D3, has been reported to be several times more potent than the parent compound regarding some vitamin D actions.

Hyperparathyroidism

Approved

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com